GANX - NASDAQ

Gain Therapeutics, Inc.

GANX·NASDAQ

$1.88

+4.7%

HealthcareBiotechnology

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$79.98M

EPS-0.6100

P/E Ratio-3.07

Earnings Date08/06/2026

22.82M

Assets

88%

3Y-5.0%

5Y+138.0%

10Y+2711.0%

4.25M

Total Liabilities

-11%

3Y-18.0%

5Y+25.0%

10Y+141.0%

18.56M

Total Equity

153%

3Y-2.0%

5Y+199.0%

10Y-2052.0%

Gain Therapeutics, Inc. Funding & Solvency Profile

GANX · NASDAQ

Current Assets

Cash & Cash Equivalents20.84M

Net Receivables802.69K

Inventory0.00

Other Current Assets596.82K

Total Current Assets22 M

Non-Current Assets

Property, Plant & Equipment409.01K

Goodwill & Intangible Assets102.84K

Long-Term Investments36.30K

Other Non-Current Assets33.70K

Total Non-Current Assets479 K

Total Assets

22.82M

Financial Health Analysis

Current Ratio

6.63x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.23x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

19 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Gain Therapeutics, Inc. Balance Sheet

GANX • NASDAQ

Gain Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	20.8M	10.4M	11.8M	7.3M	36.9M	7.5M	303.3K	400.7K
Short-Term Investments	0.0	0.0	5M	12.8M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	20.8M	10.4M	16.8M	20.1M	36.9M	7.5M	303.3K	400.7K
Net Receivables	802.7K	765.8K	242.6K	103.9K	195.4K	8.5K	44.9K	0.0
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	8.5K	8.4K	0.0
Other Receivables	802.7K	765.8K	242.6K	103.9K	195.4K	0.0	36.6K	0.0
Prepaids	0.0	81K	741.6K	208.5K	645.9K	199K	49.8K	0.0
Other Current Assets	596.8K	369.9K	0.0	640.3K	0.0	1.3M	31.5K	93.9K
Total Current Assets	22.2M	11.6M	17.8M	21.1M	37.7M	9M	429.5K	494.6K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	409K	323.3K	585.2K	804.3K	1M	552.7K	219.3K	305.8K
Intangible Assets	102.8K	134.3K	193.4K	214K	202.6K	0.0	0.0	0.0
Goodwill & Intangible Assets	102.8K	134.3K	193.4K	214K	202.6K	0.0	0.0	0.0
Long-Term Investments	36.3K	31.7K	0.0	1.9M	31.3K	0.0	10.4K	0.0
Tax Assets	0.0	0.0	0.0	0.0	-31.3K	0.0	0.0	0.0
Other Non-Current Assets	33.7K	32.1K	51.9K	48.3K	53.4K	63.8K	1K	11.2K
Total Non-Current Assets	581.8K	521.4K	830.5K	3M	1.3M	616.5K	230.8K	317K
Total Assets	22.8M	12.1M	18.6M	24.1M	39M	9.6M	660.3K	811.6K
LIABILITIES
CURRENT LIABILITIES
Total Payables	868.1K	1.2M	1.4M	1.6M	560.5K	961.5K	192.9K	149.3K
Accounts Payable	825K	946.3K	1.3M	1.6M	560.5K	961.5K	154.4K	149.3K
Other Payables	43.1K	229.3K	49K	0.0	0.0	0.0	38.5K	0.0
Accrued Expenses	0.0	2.2M	726.5K	1.7M	1.4M	762.1K	211.5K	124.4K
Short Term Debt	220.7K	110.2K	118.8K	108.1K	103.8K	22.6K	102.1K	0.0
Capital Lease Obligations (Current)	0.0	160.9K	229.7K	229.1K	219.1K	122.8K	102.1K	97.6K
Tax Payables	0.0	0.0	49K	107.3K	380.0	0.0	3.7K	0.0
Deferred Revenue	0.0	252.2K	1.1M	55.2K	266.5K	0.0	368.8K	0.0
Other Current Liabilities	2.3M	18.5K	1.4M	364.1K	380.0	245.9K	-98.4K	159.5K
Total Current Liabilities	3.4M	3.9M	4.9M	4.1M	2.6M	2.1M	879.1K	530.8K
NON-CURRENT LIABILITIES
Long Term Debt	300.1K	328.3K	449.1K	495.3K	590.5K	715.7K	0.0	1M
Deferred Revenue (Non-Current)	0.0	47.4K	94.8K	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	390.5K	443.6K	307.5K	157.6K	329.5K	171.6K	132.2K	24K
Total Non-Current Liabilities	901.8K	873K	1.1M	1.1M	1.6M	1.3M	231.1K	1.2M
Capital Lease Obligations	211.2K	214.5K	459.5K	670.9K	914.2K	523.1K	201K	298.5K
Total Liabilities	4.3M	4.8M	6M	5.2M	4.2M	3.4M	1.1M	1.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	415.0	99.0	0.0
Common Stock	4.2K	2.7K	1.6K	1.2K	1.2K	354.0	225.0	225.0
Additional Paid-In Capital	119.1M	88.8M	73.1M	57.4M	55.8M	13.4M	3.1M	309.5K
Retained Earnings	-101.4M	-81.2M	-60.8M	-38.5M	-20.9M	-7M	-3.5M	-1.3M
Accumulated Other Comprehensive Income/Loss	776.9K	-247.5K	247.2K	35.6K	-90.6K	-152.7K	-81.2K	3.1K
Total Stockholders' Equity	18.6M	7.3M	12.6M	18.9M	34.8M	6.2M	-449.9K	-950.9K
Total Equity	18.6M	7.3M	12.6M	18.9M	34.8M	6.2M	-449.9K	-950.9K
SUMMARY
Total Liabilities & Equity	22.8M	12.1M	18.6M	24.1M	39M	9.6M	660.3K	811.6K
Total Investments	36.3K	31.7K	5M	14.8M	31.3K	0.0	10.4K	0.0
Total Debt	732.1K	653K	1M	1.3M	1.6M	1.3M	201K	1.3M
Net Debt	-20.1M	-9.7M	-10.8M	-6M	-35.3M	-6.2M	-102.4K	807.1K
Shares Outstanding	35,948,606	35,948,606	35,948,606	35,948,606	35,948,606	35,948,606	35,948,606	35,948,606

SEC Filings

GANX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 26, 2026	May 26, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 24, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 18, 2026	March 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 03, 2026	February 03, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 18, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 28, 2025	November 28, 2025	2025	View Filing

Showing 1 to 10 of 95 filings

Related Guides

Blog Categories

Continue your GANX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.